I got this nice message from Astra
From: Hans.Karlsson@astra.se.astra.com
To:
Subject: FW: Vivus-owner
Date sent: Mon, 22 Jun 1998 12:56:32 +0200
> Dear
>
> Astra believes that there is room for more than one therapy against
> impotence. Muse is one of the best and has a fair potential, even
> when considering the successes of Viagra.
>
> We have introduced Muse in GB and in Sweden so far, and are in the
> process of introducing it in the rest of Europe, New Zeeland,
> Australia and Latin America. The order of these markets to start is
> not set yet.
>
> The relationship between Vivus and FDA must be a topic for them to
> comment on.
>
> Naturally, Astra will do everything to support Muse - as we do with
> all our products - at introduction to a new market. Most of the
> efforts is directed at convincing the prescribers of the exellent
> therapy that Muse offers, but we also use advertizing and PR in this
> work.
>
>
> Yours sincerely,
>
> John Ahlmark
>
My E-mail requesting information said,
From:
To: infomaster@astra.se.astra.com
Subject: Vivus
Date sent: Tue, 16 Jun 1998 12:50:43 0000
Dear Sir,
I am a shareholder in the American company Vivus. I understand that
you have an interest in Vivus and are distributing muse in Europe and
elsewhere.
I have been very concerned recently about the decline in the share
price of Vivus and the paucity of positive press releases about what
I regard as a good product. I would be grateful if you could provide
me with information regarding the following.
1. Does Astra believe that muse will be profitable given the pressure
from viagra?
2. What volume of sales in terms of muse packs (6 units) does Astra
hope to achieve this year and in 1999?
3. Which countries will you be selling muse in by end of this year?
4. Can you throw any light on the reason for the delay in FDA approval of the Vivus new plant?
5. Will Astra contribute to the dissemination of positive information
through press and media on muse?
Yours sincerely, |
